EAN

Insights from Piet Eelen on the pressures facing specialist nurses, gaps in person-centered care, and priorities for more sustainable multiple sclerosis services Specialist multiple sclerosis (MS) nurses play an important role in treatment monitoring, symptom management, patient education, and coordination ...

Phase 3 data presented at MSToronto2026 strengthen the case for oral, central nervous system-penetrant Bruton’s tyrosine kinase inhibition in multiple sclerosis. However, differences between individual agents, limited head-to-head data with high-efficacy therapies, and unanswered questions around long-term disability and safety ...

The 12th European Stroke Organisation Conference (Maastricht, May 6–8, 2026) was dominated by studies testing the limits of acute stroke therapy, from thrombectomy and neuroprotection to secondary prevention. Supplementary Table 1 provides a comprehensive overview of the major studies presented during the conference. ...

AANEM highlights emerging clinical data in myasthenia gravis and CIPD, alongside advances in imaging, biomarkers, and disease monitoring, highlight the evolving landscape of neuromuscular care The 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, held September 29–October 2 in ...

The phase 3 FUSION trial has met its primary endpoint, with the RNA-targeted therapy ulefnersen demonstrating a significant benefit across a combined measure of function and survival in people with fused in sarcoma-associated amyotrophic lateral sclerosis. Ulefnersen, an investigational antisense oligonucleotide ...

Prof. Hideo Yamanouchi discusses the lifelong impact of Dravet syndrome, the importance of adaptive functioning and genetic diagnosis, and how emerging targeted therapies could reshape treatment goals beyond seizure reduction. Dravet syndrome is increasingly understood as a lifelong genetic neurodevelopmental ...

Monthly migraine days remain a central endpoint in migraine trials and clinical practice, but do they capture what matters most to people living with migraine? At the Migraine Trust International Symposium 2026, touchNEUROLOGY spoke with Prof. Stewart J. Tepper about interictal ...

From gene-targeted approaches in Dravet syndrome to positive phase 3 data in focal and generalized seizures, selected presentations at the 16th European Epilepsy Congress highlighted a rapidly evolving epilepsy treatment landscape. Beyond reducing seizure frequency, several studies also explored whether emerging ...

Practical strategies to improve migraine recognition, optimize acute treatment, and support more consistent, individualized care in primary-care settings Migraine is a common and disabling neurological disorder that is frequently managed in primary care. However, gaps in recognition, diagnosis, and acute ...